FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Lee Tom Y
2. Issuer Name and Ticker or Trading Symbol

PURE BIOSCIENCE, INC. [ PURE ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

1807 SAN GABRIEL BLVD.
3. Date of Earliest Transaction (MM/DD/YYYY)

10/1/2019
(Street)

SAN GABRIEL, CA 91776
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  10/2/2019    P    1000000  A $0.29  22136186  I  By Plum Investments, L.P. (1)
Common Stock                 4362490  D   
Common Stock                 1000000  I  By By Kamika Shay Lee Trust Dated July 1, 2019 (2)
Common Stock                 1000000  I  By By Karissa Shay Lee Trust Dated July 1, 2019 (2)
Common Stock                 717665  I  By Wife 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)  $0.29  10/1/2019    A     150000       (3) 10/1/2029  Common Stock  150000  $0.00  150000  D   

Explanation of Responses:
(1)  Mr. Lee is the general partner and sole limited partner of Plum Investments, L.P., and has ultimate voting and investment control over the shares held by Plum Investments, L.P.
(2)  Mr. Lee is a trustee of the Kamika Shay Lee Trust Dated July 1, 2019 and Karissa Shay Lee Trust Dated July 1, 2019 and has voting and dispositive power with respect to these shares
(3)  The option shares shall vest and become exercisable in four equal installments on January 1, 2020, April 1, 2020, July 1, 2020 and October 1, 2020.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Lee Tom Y
1807 SAN GABRIEL BLVD.
SAN GABRIEL, CA 91776
X



Signatures
/s/ Tom Lee 10/3/2019
**Signature of Reporting Person Date


PURE Bioscience (PK) (USOTC:PURE)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more PURE Bioscience (PK) Charts.
PURE Bioscience (PK) (USOTC:PURE)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more PURE Bioscience (PK) Charts.

Pure Bioscience, Inc. News

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Friday 14 June 2024 (1 month ago) • Edgar (US Regulatory)
Form 8-K - Current report
Friday 14 June 2024 (1 month ago) • Edgar (US Regulatory)
Form 3 - Initial statement of beneficial ownership of securities
Monday 13 May 2024 (2 months ago) • Edgar (US Regulatory)
Form 8-K - Current report
Tuesday 7 May 2024 (2 months ago) • Edgar (US Regulatory)
Form 8-K - Current report
Monday 26 February 2024 (5 months ago) • Edgar (US Regulatory)
Form DEF 14A - Other definitive proxy statements
Wednesday 10 January 2024 (6 months ago) • Edgar (US Regulatory)
Form PRE 14A - Other preliminary proxy statements
Tuesday 19 December 2023 (7 months ago) • Edgar (US Regulatory)
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 14 December 2023 (7 months ago) • Edgar (US Regulatory)
Form 8-K - Current report
Thursday 14 December 2023 (7 months ago) • Edgar (US Regulatory)
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Monday 30 October 2023 (9 months ago) • Edgar (US Regulatory)
Form 8-K - Current report
Monday 30 October 2023 (9 months ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Thursday 3 August 2023 (12 months ago) • Edgar (US Regulatory)